ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments (EN/FR/NL)

  • Accelerated clinical development of ExeVir’s novel llama-derived antibody therapies for potential treatment and prevention of Covid-19
  • Manufacturing of ExeVir’s candidate product at Mithra CDMO’s new Injectable Facility
  • Joint unique expertise of two Belgian biotechs to provide global access to innovative therapies for a broad range of coronaviruses, including variants of concern

15 July 2021, 07:30 CEST, Belgium: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH